Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
J. bras. pneumol ; 36(6): 819-823, nov.-dez. 2010. ilus
Article in Portuguese | LILACS | ID: lil-570655

ABSTRACT

A doença de Castleman é um distúrbio linfoproliferativo atípico, de etiologia desconhecida, que pode estar associada a uma série de condições clínicas, inclusive doenças de caráter autoimune e neoplasias malignas. No presente relato, uma paciente de 72 anos foi encaminhada ao serviço de cirurgia torácica do Hospital Universitário Getúlio Vargas, localizado na cidade de Manaus (AM) para a ressecção de um tumor de mediastino posterior. Três meses antes, havia sido internada em UTI com um quadro de dispneia intensa, ocasião na qual foi diagnosticada miastenia gravis. Após a ressecção da massa mediastinal, a análise histopatológica revelou doença de Castleman hialino-vascular complicada por sarcoma de células dendríticas foliculares. Até o momento da redação deste estudo, a paciente utilizava um anticolinesterásico e corticoides para o controle da miastenia gravis.


Castleman's disease is an atypical lymphoproliferative disorder of unknown etiology, which might be associated with various clinical conditions, including autoimmune diseases and malignant neoplasms. We report the case of a 72-year-old female patient who was referred to the thoracic surgery department of Getúlio Vargas University Hospital, in the city of Manaus, Brazil, for the resection of a posterior mediastinal tumor. Three months prior, the patient had been admitted to the ICU with signs of severe dyspnea, at which time she was diagnosed with myasthenia gravis. After the resection of the mediastinal tumor, the histopathological examination revealed hyaline vascular-type Castleman's disease, complicated by follicular dendritic cell sarcoma. At this writing, the patient was being treated with an anticholinesterase agent and corticosteroids for the control of myasthenia gravis.


Subject(s)
Aged , Female , Humans , Dendritic Cell Sarcoma, Follicular/complications , Castleman Disease/complications , Myasthenia Gravis/diagnosis , Diagnosis, Differential , Dendritic Cell Sarcoma, Follicular/pathology , Castleman Disease/classification
2.
J Bras Pneumol ; 36(6): 819-23, 2010.
Article in English, Portuguese | MEDLINE | ID: mdl-21225186

ABSTRACT

Castleman's disease is an atypical lymphoproliferative disorder of unknown etiology, which might be associated with various clinical conditions, including autoimmune diseases and malignant neoplasms. We report the case of a 72-year-old female patient who was referred to the thoracic surgery department of Getúlio Vargas University Hospital, in the city of Manaus, Brazil, for the resection of a posterior mediastinal tumor. Three months prior, the patient had been admitted to the ICU with signs of severe dyspnea, at which time she was diagnosed with myasthenia gravis. After the resection of the mediastinal tumor, the histopathological examination revealed hyaline vascular-type Castleman's disease, complicated by follicular dendritic cell sarcoma. At this writing, the patient was being treated with an anticholinesterase agent and corticosteroids for the control of myasthenia gravis.


Subject(s)
Castleman Disease/complications , Dendritic Cell Sarcoma, Follicular/complications , Myasthenia Gravis/diagnosis , Aged , Castleman Disease/classification , Dendritic Cell Sarcoma, Follicular/pathology , Diagnosis, Differential , Female , Humans
3.
J Headache Pain ; 8(5): 301-5, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17955169

ABSTRACT

Headache induced by acute exposure to a specific drug constitutes an idiosyncratic side effect. Metabolic imbalance appears as the leading aetiology, among several other hypotheses. Either primary headaches show a higher susceptibility to this idiosyncratic reaction or a drug-induced primary headache evolves in intensity and duration, becoming uncontrolled until the complete discontinuation of the drug in consideration. The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into status migrainosus after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (CBZ). Twenty-four to seventy-two hours following the switch, all patients developed intractable headache, despite the use of different symptomatic drugs. Complete recovery of the headache symptoms occurred only after OXC was discontinued. We discuss the potential mechanisms associated to OXC and status migrainosus, drug-induced headaches and uncontrolled headaches.


Subject(s)
Brain Neoplasms/complications , Carbamazepine/analogs & derivatives , Epilepsy/complications , Headache Disorders/chemically induced , Migraine Disorders/chemically induced , Neoplasms, Neuroepithelial/complications , Acute Disease , Adult , Anticonvulsants/adverse effects , Brain Neoplasms/diagnosis , Carbamazepine/adverse effects , Central Nervous System Vascular Malformations/complications , Central Nervous System Vascular Malformations/diagnosis , Disease Progression , Epilepsy/drug therapy , Female , Headache Disorders/physiopathology , Humans , Migraine Disorders/physiopathology , Neoplasms, Neuroepithelial/diagnosis , Oxcarbazepine
SELECTION OF CITATIONS
SEARCH DETAIL
...